BRAFV600E mutation and x-linked inhibitor of apoptosis expression in papillary thyroid carcinoma

Thyroid

Volumn 19, Issue 4, 2009, Pages 347-354

  Gu, Li Qun ^a   Li, Feng Ying ^a   Zhao, Lin ^a   Liu, Yun ^a   Zang, Xun Xiong ^b   Wang, Tian Xiang ^c   Chen, Hui Ping ^d   Ning, Guang ^a   Zhao, Yong Ju ^a,e  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Le qing People's Hospital   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d Western Medicine Hospital   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; X LINKED INHIBITOR OF APOPTOSIS; BRAF PROTEIN, HUMAN; XIAP PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AMINO ACID SUBSTITUTION; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER INVASION; CANCER SIZE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NODULAR GOITER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA; GENETICS; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; THYROID TUMOR;

ADULT; AMINO ACID SUBSTITUTION; CARCINOMA, PAPILLARY; FEMALE; GOITER, NODULAR; HASHIMOTO DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 66749153133     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0246     Document Type: Article

References (41)

1. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
2. Shibru D, Chung KW, Kebebew E 2008 Recent developments in the clinical application of thyroid cancer biomarkers. Curr Opin Oncol 20:13-18.
3. Ciampi R, Nikiforov YE 2007 RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148:936-941.
4. Nikiforova MN, Nikiforov YE 2008 Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8:83-95.
5. Mercer KE, Pritchard CA 2003 Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25-40.
6. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenical role, molecular bases, and clinical implications. Endocr Rev 28:742-762.
7. Liu D, Liu Z, Condouris S, Xing M 2007 BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 92:2264-2271.
8. Salvesen GS, Duckett CS 2002 IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3:401-410.
9. Deveraux QL, Reed JC 1999 IAP family proteins -suppressors of apoptosis. Genes Dev 13:239-252.
10. Tirro E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A, Vigneri P 2006 Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 66:4263-4272.
11. Eckelman BP, Salvesen GS, Scott FL 2006 Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 7:988-994.
12. Barkett M, Gilmore TD 1999 Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18:6910-6924.
13. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K, Yamashita S 2006 BRAF V600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 147:5699-5707.
14. Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C, Seruca R 2008 BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAFV600E but not KRAS mutations. J Pathol 214:320-327.
15. Xiao GQ, Unger PD, Burstein DE 2007 Immunohisto-chemical detection of X-linked inhibitor of apoptosis (XIAP) in neoplastic and other thyroid disorders. Ann Diagn Pathol 11:235-240.
16. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R 2006 Correlation between B-RAFV600E mutation and clinicopathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13:455-464.
17. Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, Elashoff D, Hoon DS 2006 Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 244:799-804.
18. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404.
19. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F 2007 Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92:4085-4090.
20. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397.
21. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R 2008 BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 15:191-205.
22. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379.
23. Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, Elisei R, Santoro M, Basolo F 2007 Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 17:381-388.
24. Wang Y, Ji M, Wang W, Miao Z, Hou P, Chen X, Xu F, Zhu G, Sun X, Li Y, Condouris S, Liu D, Yan S, Pan J, Xing M 2008 Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer 15:183-190.
25. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK 2006 The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 65:364-368.
26. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F 2004 BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89:2414-2420.
27. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT 2005 No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 63:461-466.
28. Mazzaferri EL 2000 Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 6:469-476.
29. Lu M, Lin SC, Huang Y, Kang YJ, Rich R, Lo YC, Myszka D, Han J, Wu H 2007 XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol Cell 26:689-702.
30. Endo T, Abe S, Seidlar HB, Nagaoka S, Takemura T, Utsuyama M, Kitagawa M, Hirokawa K 2004 Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol Immunother 53:770-776.
31. Nemoto T, Kitagawa M, Hasegawa M, Ikeda S, Akashi T, Takizawa T, Hirokawa K, Koike M 2004 Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol 76:253-259.
32. Danson S, Dean E, Dive C, Ranson M 2007 IAPs asa target for anticancer therapy. Curr Cancer Drug Target 7:785-794.
33. Ekedahl J, Joseph B, Grigoriev MY, Müller M, Magnusson C, Lewensohn R, Zhivotovsky B 2002 Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp Cell Res 279:277-290.
34. Liu SS, Tsang BK, Cheung AN, Xue WC, Cheng DK, Ng TY, Wong LC, Ngan HY 2001 Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer 37:1104-1110.
35. Sheils O, Smyth P, Finn S, Sweeney EC, O'Leary JJ 2001 RET/PTC rearrangements in Hashimoto's thyroiditis. Int J Surg Pathol 10:167-168.
36. Arif S, Blanes A, Diaz-Cano SJ 2002 Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology 41:357-362.
37. Arscott PL, Stokes T, Myc A, Giordano TJ, Thompson NW, Baker JR Jr 1999 Fas (CD95) expression is upregulated on papillary thyroid carcinoma. J Clin Endocrinol Metab 84:4246-4252.
38. Tanimoto C, Hirakawa S, Kawasaki H, Hayakawa N, Ota Z 1995 Apoptosis in thyroid diseases: a histochemical study. Endocr J 42:193-201.
39. Dubrez-Daloz L, Dupoux A, Cartier J 2008 IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 7:1036-1046.
40. Zehntner SP, Bourbonnière L, Moore CS, Morris SJ, Methot D, St Jean M, Lacasse E, Hebb AL, Robertson GS, Durkin J, Gillard JW, Owens T 2007 X-linked inhibitor of apoptosis regulates T cell effector function. J Immunol 179:7553-7560.
41. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, eds. 2002 AJCC cancer staging manual. 6th ed. New York, Berlin, Heidelberg, Springer-Verlag; 77-87.